Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says

Emily Field, Barclays’ head of European pharmaceutical research, reacts to the selloff in Novo Nordisk's shares after its experimental obesity shot CagriSema failed to meet expectations. She speaks on "Bloomberg Open Interest."

--------
More on Bloomberg Television and Markets


Connect with Bloomberg Television on:

Connect with Bloomberg Business on:

More from Bloomberg:


Watch more on YouTube:

[cupajoe]

Clearly a overreaction. We are talking a few percent. Weak hands will regret when they watch it go back to triple digits

[fair-value]

Agree, this is an overreaction, chance to buy a great business at a fair or even bargain price compared to even a few months ago

[chrisja]

Glad I bought up big today. Remember Novo is earning big even with this drop, currently only rich people can buy these products. Imagine when everyone who needs it can afford it. It will be cash flow, every year all the time.

[AliAhmad-grhk]

The sell off is stupid and great opportunity to buy . The results of the study is good. Basically this new drug has better results than Lilly’s zepbound. Furthermore it showed 22% weight loss in lesser weeks vs zepbound. This a great opportunity to buy this stock.

[AbdulSalam-ztkz]

People… people don’t trade pre-market. Stop talking about ordinary retail investors. Maybe instutional investors sold before the year end for tax reasons and they will buy the stock again in January

[AyseDiana]

Alemio Network’s presale is happening now, and it’s the perfect time to invest before this project goes mainstream. Don’t sleep on this one!

[LizzieMcewen]

Top tier presale just begun. I think Alemio Network is one of the most promissing projects year to date.

[glennnielsen]

It's about odds, I think it's mostly likely the odds are on her side.

[KenanSafak-gr]

Guys, Alemio’s team seems solid, and their vision is ambitious. Definitely one to watch.

[DuyguTugrul-qq]

The roadmap for Alemio is super ambitious. If they can deliver on even half of it, we’re in for a massive ride. ALM to the moon?

[MehriYasemin]

BTC will go over 100k in the next year or two, that is approx 3x. Alemio can do 100x if you get positioned well. Just check it out

[OzgurMahmut]

What if I told you that Alemio Network will crush most of the top tier AI coins by the end of the year?

[inciKubilay-fx]

This is one-in-a-bull-run opportunity, you don´t wanna miss Alemio Network presale

[SebahatEmre]

Ethereum will outperform Bitcoin in the following year, Alemio Network will outperform them both by far.

[Dronk]

Definitely not an overreaction. There is no room for errors with more options. CS is a difficult product to make, and the safety profile reported doesnt look too bright. We did have information on side effects as only 6 out of 10 people reached maximum dose, which doesnt spell good news. Retatrutide already reported higher numbers in much shorter time.

[kubes]

murican news in nutshell, only informing narcissistic attitude on things, bad at separating emotions from math.

[DavidTomas-th]

ey everyone, Alemio’s roadmap is ambitious, but it looks like they’ve got a strong team behind it.

[FredrickaFahey]

Hey guys, Alemio’s vision for AI-driven blockchain solutions is interesting. Took part in the presale today.

[RobenaMadison]

Anyone else noticing how quiet Alemio Network is flying under the radar? This is usually how the big gains sneak up on you!

[JARODSalerno]

Hey folks, Alemio’s presale is filling up quickly. Locked in my tokens just in time!